An open label, randomised controlled trial of the effects of Liraglutide and Acarbose on glycaemic control, weight and Health Related Quality Of Life (HRQOL) in Overweight type 2 Diabetic patients on Oral Hypoglycaemic Agents (OHAs) and high doses of insulin.

Trial Profile

An open label, randomised controlled trial of the effects of Liraglutide and Acarbose on glycaemic control, weight and Health Related Quality Of Life (HRQOL) in Overweight type 2 Diabetic patients on Oral Hypoglycaemic Agents (OHAs) and high doses of insulin.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Liraglutide (Primary) ; Acarbose
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms Lirabose1
  • Most Recent Events

    • 23 Jun 2015 Status changed from completed to discontinued as per ISRCTN record.
    • 19 Jul 2014 Accrual to date is 71% according to United Kingdom Clinical Research Network record.
    • 01 Dec 2012 Status changed from unconfirmed to completed as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top